CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Company profile
Ticker
CYTR
Exchange
Website
CEO
Steven A. Kriegsman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
Corporate docs
Subsidiaries
Centurion BioPharma Corporation ...
IRS number
581642750
CYTR stock data
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
12 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.11M | 4.11M | 4.11M | 4.11M | 4.11M | 4.11M |
| Cash burn (monthly) | 321.96K | 360.25K | 382.68K | 1M | 254.44K | 1.08M |
| Cash used (since last report) | 467.68K | 523.29K | 555.87K | 1.46M | 369.6K | 1.56M |
| Cash remaining | 3.64M | 3.59M | 3.56M | 2.65M | 3.74M | 2.55M |
| Runway (months of cash) | 11.3 | 10.0 | 9.3 | 2.6 | 14.7 | 2.4 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Jan 22 | Stephen Snowdy | Stock Appreciation Right Common Stock | Grant | Acquire A | No | No | 0.641 | 300,000 | 192.3K | 300,000 |
| 15 Dec 21 | Simpson Jennifer K. | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0 | 25,000 |
| 15 Dec 21 | Simpson Jennifer K. | Stock Appreciation Right Common Stock | Grant | Acquire A | No | No | 0.45 | 50,000 | 22.5K | 50,000 |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Financial report summary
?Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
Coll freshman Bad
|
|
New words:
aberrant, absolute, abundant, Additionally, assumption, automatically, binding, Bio, cell, central, chemotherapy, CNS, death, Denmark, detect, detected, Eastern, economy, error, excellent, experimental, experimentation, fraud, GLP, GmbH, Good, growth, horse, Immunity, immunotherapy, inflation, inflationary, inside, interval, KemPharm, maintenance, matter, met, nutritional, parallel, past, plasma, protein, pursue, put, question, range, rare, run, sarcoma, showing, signaling, Society, specialty, structure, transport, trojan, uncommon, vascular, wholly
Removed:
accumulation, antibody, cytotoxic, efficacy, enhance, enrollment, failed, fully, gastrointestinal, highlighted, Kriegsman, located, medicine, personalized, Steven, testing, therapeutic
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
27 Jul 22
8-K
Departure of Directors or Certain Officers
2 Jun 22
8-K
CytRx Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
19 May 22
8-K
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
21 Mar 22
8-K
Material Modifications to Rights of Security Holders
16 Mar 22
8-K
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
10 Mar 22
8-K
FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares
17 Feb 22
8-K
Regulation FD Disclosure
26 Jan 22
8-K
CytRx Announces the Appointment of Dr. Stephen
4 Jan 22
8-K
Departure of Directors or Certain Officers
16 Dec 21
Registration and prospectus
D/A
$18.24M in equity / options / securities to be acquired, sold $8.24M, 1 investor
28 Jul 22
424B3
Prospectus supplement
25 Mar 22
S-1/A
IPO registration (amended)
23 Mar 22
S-1
IPO registration
4 Aug 21
D
$18.24M in equity / options / securities to be acquired, sold $8.24M, 1 investor
29 Jul 21
424B5
Prospectus supplement for primary offering
15 Jul 21
S-3/A
Shelf registration (amended)
14 May 21
S-3
Shelf registration
22 Apr 21
S-8
Registration of securities for employees
23 Oct 20
25-NSE
Exchange delisting
24 Jun 19
Proxies
DEFA14A
Additional proxy soliciting materials
16 Jun 22
DEFA14A
Additional proxy soliciting materials
16 Jun 22
DEFA14A
Additional proxy soliciting materials
17 Feb 22
DEF 14A
Definitive proxy
31 Jan 22
DEFA14A
Additional proxy soliciting materials
26 Jan 22
PRE 14A
Preliminary proxy
21 Jan 22
DEFA14A
Additional proxy soliciting materials
9 Sep 21
DEFA14A
Additional proxy soliciting materials
16 Aug 21
Other
EFFECT
Notice of effectiveness
28 Mar 22
CORRESP
Correspondence with SEC
22 Mar 22
UPLOAD
Letter from SEC
9 Aug 21
EFFECT
Notice of effectiveness
13 Jul 21
CORRESP
Correspondence with SEC
11 Jul 21
UPLOAD
Letter from SEC
28 Apr 21
UPLOAD
Letter from SEC
11 Aug 20
UPLOAD
Letter from SEC
30 Jul 20
UPLOAD
Letter from SEC
21 Jul 20
UPLOAD
Letter from SEC
12 Jul 20
Ownership
3
CYTRX / Cary J Claiborne ownership change
28 Jul 22
SC 13G
CYTRX / ARMISTICE CAPITAL ownership change
14 Feb 22
4
CYTRX / Stephen Snowdy ownership change
12 Jan 22
3
CYTRX / Stephen Snowdy ownership change
12 Jan 22
4/A
CYTRX / Jennifer K. Simpson ownership change
11 Jan 22
4
CYTRX / Jennifer K. Simpson ownership change
17 Dec 21
3
CYTRX / Jennifer K. Simpson ownership change
11 Aug 21
4
CYTRX / Earl W Brien ownership change
20 Aug 20
4
CYTRX / STEVEN A KRIEGSMAN ownership change
13 Aug 20
4
CYTRX / LOUIS IGNARRO ownership change
13 Aug 20
Patents
Utility
Delivery systems for controlled drug release
12 Jul 22
Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
Utility
Albumin-binding prodrugs of auristatin E derivatives
5 Jul 22
The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
Utility
Cytotoxic agents for the treatment of cancer
4 Jan 21
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.
Utility
Cytotoxic Agents for the Treatment of Cancer
20 Nov 19
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolytically or enzymatically in the body of the patient in a pH-dependent manner.